Teva- Pharmaceutical Industries Ltd.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.www.tevapharm.com
83
MENTIONS
44
EPISODES
31
PODCASTS
Search complete. 83 mentions across 44 episodes found for "Teva- Pharmaceutical Industries Ltd.".
Sep 9, 2026
Dave WallaceGUEST
I mean, it's an interesting claim because obviously there are companies that are just doing generics or just doing biosimilars.
Dave WallaceGUEST
But I think the way Sandoz are trying to position themselves is that in among the largest companies in the sector, you know, their peers are people like Teva, people like Viatris.
Dave WallaceGUEST
Those companies are going after specialty opportunities.
Dave WallaceGUEST
They're going after 505B2 opportunities.
Tina GarveyNARRATOR
For more than 14 years, he has worked to bring the patient and community perspective into healthcare and biopharmaceutical organisations, helping ensure that the experiences and priorities of people living with disease are reflected in decision-making.
Tina GarveyNARRATOR
Originally from the UK and now based in Amsterdam, Andy began his career with the Association of the British Pharmaceutical Industry before joining Teva, Biogen ProQR Therapeutics and now TEA.
Tina GarveyNARRATOR
Throughout his career, he has partnered closely with patient organisations and community leaders across a range of disease areas, including neurological, respiratory and inherited retinal diseases.
Tina GarveyNARRATOR
Andy is passionate about building genuine partnerships with patient communities and believes that listening to and learning from lived experience is essential to improving healthcare, research and treatment development.
Mike SlaterHOST
Huge Trump win here.
Mike SlaterHOST
He had nine pharmaceutical company leaders in the Oval Office the other day.
Mike SlaterHOST
all of them committed to lowering drug prices for you.
Mike SlaterHOST
This is a part of Trump's most favored nation pricing.
Mike SlaterHOST
Precursor chemicals made in China to make our medicine is crazy.
Mike SlaterHOST
So just like the strategic petroleum reserves, we now have a six-month supply of all these pharmaceutical ingredients at all times.
Mike SlaterHOST
So for instance, this company, Teva Pharmaceuticals, they're contributing 45 metric tons of metronidazole, an antibiotic, and antiprotozoal used to treat bacteria and parasitic infections, and 4.8 tons of amlodiphene, An anti-hypertensive drug.
Mike SlaterHOST
Whatever, they sound important.
Maya PatelHOST
Magnitude is the thing every one of those franchise plans actually needs.
Alex MercerHOST
Staying in the pipeline, Teva's anti-IL-15 antibody, Tev-E408, hit its primary endpoint in a 50-patient Phase IIa in celiac disease.
Alex MercerHOST
One subcutaneous dose, then six weeks of daily gluten, and the treated arm showed significantly less intestinal damage on biopsy than placebo.
Alex MercerHOST
Teva calls it pipeline in a product.
Alex MercerHOST
A Phase IIb in vitiligo is already moving, with up to $500 million of royalty pharma funding behind the program.
Maya PatelHOST
50 patients in one dose.
Maya PatelHOST
One policy item before we close the segment.
Maya PatelHOST
The White House added nine more manufacturers to its most favored nation pricing agreements on Monday.
Mike SlaterCORRESPONDENT
Huge Trump win here.
Mike SlaterCORRESPONDENT
He had nine pharmaceutical company leaders in the Oval Office the other day.
Mike SlaterCORRESPONDENT
all of them committed to lowering drug prices for you.
Mike SlaterCORRESPONDENT
This is a part of Trump's most favored nation pricing.
Mike SlaterCORRESPONDENT
Precursor chemicals made in China to make our medicine is crazy.
Mike SlaterCORRESPONDENT
So just like the strategic petroleum reserves, we now have a six-month supply of all these pharmaceutical ingredients at all times.
Mike SlaterCORRESPONDENT
So for instance, this company, Teva Pharmaceuticals, they're contributing 45 metric tons of metronidazole, an antibiotic, an antiprotozoal used to treat bacteria and parasitic infections, and 4.8 tons of amlodiphene, An anti-hypertensive drug.
Mike SlaterCORRESPONDENT
Whatever.
Jeff AxtHOST
In total, according to the White House, MFN deals now cover some 89% of the branded drug market.
Annalee ArmstrongHOST
Yeah, so among the companies that have now signed on to this include Astellas Pharma, B1 Medicines, UCB, and Teva.
Annalee ArmstrongHOST
The companies have collectively committed nearly $20 billion in manufacturing investments in the U.S., the White House announced at the same time.
Annalee ArmstrongHOST
So that brings the full coverage of MFN to about 89% of branded drugs in the U.S. Analysts have said that the agreements were a positive move for these companies and could shield them from some tariff concerns, some other initiatives of the White House.
Donald TrumpSOUNDBITE_SPEAKER
They're largely standing behind me.
Donald TrumpSOUNDBITE_SPEAKER
I want to thank The president of Astellas Pharma Medical, Michael Putratis, and CEO of B1 Medicines, John Euler, CEO of Bridge Bio, Neil Kumar, Senior Vice President of CSL, Julie Schiffman, CEO of Sun Pharma, Rick Ashcroft, President of Keio Kirin, Steve Schaefer, Executive Vice President of Teva Pharmaceuticals USA, Christine Fox, CEO of UCB, Dr. Jean-Christophe Tellier.
Donald TrumpSOUNDBITE_SPEAKER
I think I got those names almost right.
Donald TrumpSOUNDBITE_SPEAKER
That's a group of very interesting names.
Ryan GableGUEST
When I looked into that, I found, oh, actually, since the '80s, we've known that it's, it's the Israeli, uh, military that trains, arms, finances, and runs most of the South Central American drug cartels.
Ryan GableGUEST
And they run most of the, of the legal drug cartels too, because from Teva Pharmaceuticals or Purdue Pharmaceuticals, they're behind the opioid crisis.
Ryan GableGUEST
They're behind the gender, uh, affirming hormone therapy, the GAT drugs, that's Teva Pharmaceuticals.
Ryan GableGUEST
By the way, and for the record, I just literally learned this yesterday, uh, Teva Pharmaceuticals is also behind the alternative treatment to SARS-CoV-2.
Ryan GableGUEST
They're behind hydroxychloroquine as well.
Ryan GableGUEST
So...
Mike ChristelHOST
GSK pushes its dual antigen mRNA flu vaccine, FLUM, 3HA.B-3NA into a first-of-its-kind Phase III trial, and Simseer Zymine Licenses, its tri-specific antibody, Sim-0660-Taroche, in a deal worth up to $1.53 billion.
Mike ChristelHOST
The Trump administration adds nine mid-sized drug makers, including Teva Pharmaceuticals, CSL, and UCB, to its Most Favored Nation pricing program.
Mike ChristelHOST
requiring the companies to price their medications at the lowest rate offered in other developed nations across all U.S. Medicaid programs.
Mike ChristelHOST
The nine collectively committed to investing at least $19.6 billion in U.S. manufacturing and contributing active pharmaceutical ingredients, including UCB's stockpile of the anticonvulsant levotiracetam to a new strategic active pharmaceutical ingredients reserve.
Michael NeumeisterUNKNOWN
And we view this Chapter 11 really as the next step of that months-long process in pursuing a value-maximizing transaction for all stakeholders.
Michael NeumeisterUNKNOWN
We did ultimately land on and execute a stocking horse purchase agreement with Teva Pharmaceuticals, a well-known publicly traded pharmaceuticals company.
Michael NeumeisterUNKNOWN
The purchase agreement was extensively negotiated.
Michael NeumeisterUNKNOWN
PROVIDES FOR AN UPFRONT CASH PAYMENT OF $57.5 MILLION DUE AT CLOSING AND UP TO AN ADDITIONAL $67.5 MILLION OF MILESTONE PAYMENTS, WHICH ARE TIED PRIMARILY TO THE TIMING OF SNDA APPROVAL OF THE SURROUNDING PROGRAM.
34 more episodes mention Teva- Pharmaceutical Industries Ltd..
Create an account to see the whole feed, search across every transcript, and follow the entities you care about.